Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023 - Marketscreener.com
| PRRUF Stock | USD 0.20 0.00 0.00% |
Roughly 62% of Immutep's investor base is looking to short. The analysis of overall sentiment of trading Immutep Limited pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Immutep's historical and current headlines, can help investors time the market. In addition, many technical investors use Immutep Limited stock news signals to limit their universe of possible portfolio assets.
Immutep pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Immutep daily returns and investor perception about the current price of Immutep Limited as well as its diversification or hedging effects on your existing portfolios.
Immutep |
Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023 Marketscreener.com
Read at news.google.com
 |
Immutep Fundamental Analysis
We analyze Immutep's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immutep using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immutep based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Immutep is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Immutep Limited Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immutep pink sheet to make a market-neutral strategy. Peer analysis of Immutep could also be used in its relative valuation, which is a method of valuing Immutep by comparing valuation metrics with similar companies.
Peers
Immutep Related Equities
| CDTX | Cidara Therapeutics | 8.69 | ||||
| ALXO | Alx Oncology | 1.41 | ||||
| APLT | Applied Therapeutics | 0.88 | ||||
| ZURA | Zura Bio | 0.45 | ||||
| GPCR | Structure Therapeutics | 0.63 | ||||
| ALVR | Allovir | 0.80 | ||||
| ZNTL | Zentalis Pharmaceuticals | 0.96 | ||||
| ENVB | Enveric Biosciences | 1.29 | ||||
| CRNX | Crinetics Pharmaceuticals | 1.37 | ||||
| AADI | Aadi Bioscience | 2.07 | ||||
| CGEM | Cullinan Oncology | 2.13 | ||||
| SLN | Silence Therapeutics | 2.27 | ||||
| CYTK | Cytokinetics | 2.49 | ||||
| VRDN | Viridian Therapeutics | 2.78 | ||||
| CTMX | CytomX Therapeutics | 3.57 | ||||
| ELEV | Elevation Oncology | 4.42 | ||||
| OLMA | Olema Pharmaceuticals | 5.95 | ||||
| ADCT | ADC Therapeutics | 7.07 | ||||
| SANA | Sana Biotechnology | 7.35 | ||||
| IMMX | Immix Biopharma | 8.19 | ||||
| DSGN | Design Therapeutics | 11.40 |
Complementary Tools for Immutep Pink Sheet analysis
When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |